Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
View Patent ↗A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.
1. A method for enhancing an immune response in a subject to an antigenic polypeptide, comprising:
administering to the subject an antigenic polypeptide; and
administering to the subject a therapeutically effective dose of an adenosine A2a receptor antagonist and/or an inhibitor of extracellular adenosine, wherein the adenosine A2a receptor antagonist and/or an inhibitor of extracellular adenosine enhances an immune response stimulated by the antigenic polypeptide.
2. The method of claim 1 , wherein the adenosine A2a receptor antagonist is ZM241385 (4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-α][1,3,5]triazin-5yl-amino]ethyl)phenol), 1,3,7-trimethylxanthine (caffeine), theophylline, theobromine, SCH 58261, or KW-6002.
3. The method of claim 1 , wherein the adenosine A2a receptor antagonist is ZM241385 (4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-α][1,3,5]triazin-5yl-amino]ethyl)phenol), 1,3,7-trimethylxanthine (caffeine), or KW-6002.
4. The method of claim 1 , wherein the inhibitor of extracellular adenosine is an oxygenation agent, a redox-potential changing agent, adenosine deaminase, adenosine kinase, ADA-PEG, oxygenation of the subject, or combinations thereof.
5. The method of claim 1 , wherein the antigenic polypeptide is a viral antigenic polypeptide.
6. The method of claim 1 , wherein the antigenic polypeptide is a bacterial antigenic polypeptide.
7. The method of claim 5 , wherein the viral antigenic polypeptide is present in a live, attenuated, or heat killed vaccine.
8. The method of claim 1 , wherein enhancing the immune response comprises increasing an activity of an immune cell in the subject.
9. The method of claim 8 , wherein the immune cell is a cell that produces one or more pro-inflammatory cytokines.
10. The method of claim 8 , wherein the immune cell is a macrophage, granulocyte, monocyte, neutrophil, dendritic cell, T cell, B cell, or natural killer cell.
11. The method of claim 10 , wherein the immune cell is a B cell and wherein the activity is antibody production.
12. The method of claim 10 , wherein the immune cell is a macrophage, granulocyte, monocyte, or dendritic cell, and wherein the activity is pro-inflammatory cytokine production.
13. The method of claim 1 , wherein enhancing the immune response comprises increasing antigen-specific antibody titers in the subject.
14. The method of claim 1 , wherein the immune response is a pro-inflammatory cytokine response.
15. The method of claim 14 , wherein the pro-inflammatory cytokine response is an increase in IL-12p40 and/or TNF-α mRNA expression.
16. The method of claim 1 , wherein the subject is immunocompromised.
17. The method of claim 16 , wherein the subject is infected with an immunodeficiency virus.
18. The method of claim 17 , wherein the immunodeficiency virus is HIV-1 or HIV-2.
19. The method of claim 16 , wherein the subject is receiving immunosuppressive therapy.
20. The method of claim 1 , further comprising administering an adjuvant to the subject.
21. The method of claim 6 , wherein the subject is a mammalian subject infected with a bacterial pathogen.
22. The method of claim 5 , wherein the subject is a mammalian subject infected with a viral pathogen.